艾滋病高危人群暴露前预防服药依从性评估工具的研究进展

doi:10.3761/j.issn.0254-1769.2022.19.018

摘要/Abstract

摘要：

暴露前预防指当面临HIV感染高风险时,通过服用药物以降低被感染概率的生物学预防方法。服药依从性是决定暴露前预防效果的关键因素。该文对国内外开发的暴露前预防服药依从性评估工具进行综述,包括评估工具的主要内容、应用现状及优缺点,以期为准确评估艾滋病高危人群服药依从性和制订干预方案提供参考。

关键词: 艾滋病, 高危人群, 暴露前预防, 依从性, 评估工具, 综述, 护理

Abstract:

Pre-exposure prophylaxis refers to a biological prevention method to reduce the probability of HIV infection by taking drugs when people are at high risk of HIV infection. Medication compliance is the key cause of determining the effectiveness of pre-exposure prophylaxis. This article discusses the medication compliance assessment tools of pre-exposure prophylaxis developed at home and abroad which includes the main contents of assessment tools,application status and advantages and disadvantages,expecting to provide references for accurately evaluating medication compliance of high-risk population of AIDS and formulating intervention programs.

Key words: AIDS, High-Risk Population, Pre-Exposure Prophylaxis, Adherence, Assessment Tools, Review, Nursing Care

陈玉崟, 杨连招, 龙秀红, 田怡, 谭如意, 姚胜男. 艾滋病高危人群暴露前预防服药依从性评估工具的研究进展[J]. 中华护理杂志, 2022, 57(19): 2422-2427.

CHEN Yuyin, YANG Lianzhao, LONG Xiuhong, TIAN Yi, TAN Ruyi, YAO Shengnan. Research progress of pre-exposure prophylaxis medication adherence assessment tools in high-risk population of AIDS[J]. Chinese Journal of Nursing, 2022, 57(19): 2422-2427.

参考文献 41

[1]	何加敏, 朱政, 卢洪洲. HIV感染者合并慢性非传染性疾病多药依从性管理的研究进展[J]. 中华护理杂志, 2022, 57(14): 1788-1793. DOI URL
	He JM, Zhu Z, Lu HZ. Research progress on polypharmacy adherence management in HIV-infected people with chronic non-communicable diseases[J]. Chin J Nurs, 2022, 57(14):1788-1793. DOI URL
[2]	He N. Research progress in the epidemiology of HIV/AIDS in China[J]. China CDC wkly, 2021, 3(48):1022-1030.
[3]	Nations U. Political declaration on HIV and AIDS:ending inequalities and getting on track to end AIDS by 2030[EB/OL]. (2021-06-09)[2022-04-30]. https://undocs.org/A/RES/75/284.
[4]	方鹏骞, 张佳慧, 徐娟. 我国艾滋病高危人群定义与范畴的界定[J]. 中国艾滋病性病, 2006, 12(5):470-471.
	Fang PQ, Zhang JH, Xu J. Definition and category of AIDS high-risk groups in China[J]. China J AIDS & STD, 2006, 12(5):470-471.
[5]	中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 协和医学杂志, 2022, 13(2):203-226.
	Acquired Immunodeficiency Syndrome and Hepatitis C Professional Group, Society of Infectious Diseases,Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome(2021 edition)[J]. Med J Peking Union Med Coll Hosp, 2022, 13(2):203-226.
[6]	Huang XJ, Hou JH, Song AX, et al. Efficacy and safety of oral TDF-based pre-exposure prophylaxis for men who have sex with men:a systematic review and meta-analysis[J]. Front Phar-macol, 2018, 9:799.
[7]	Jin FY, Amin J, Guy R, et al. Adherence to daily HIV pre-exposure prophylaxis in a large-scale implementation study in New South Wales,Australia[J]. AIDS, 2021, 35(12):1987-1996. DOI URL
[8]	Wang HY, Wang ZX, Huang XJ, et al. Association of HIV preexposure prophylaxis use with HIV incidence among men who have sex with men in China:a nonrandomized controlled trial[J]. JAMA Netw Open, 2022, 5(2):e2148782.
[9]	Mboup A, Diabaté S, Béhanzin L, et al. Determinants of HIV preexposure prophylaxis adherence among female sex workers in a demonstration study in cotonou,benin:a study of behavioral and demographic factors[J]. Sex Transm Dis, 2021, 48(8):565-571. DOI URL
[10]	杨雪, 康文婷, 庞琳, 等. 国内外推广人类免疫缺陷病毒暴露前预防的主要障碍及其应对措施研究进展[J]. 中国病毒病杂志, 2022, 12(1):74-80.
	Yang X, Kang WT, Pang L, et al. Major obstacles and countermeasures to the wider use of HIV pre-exposure prophylaxis:a review of worldwide research progress[J]. Chin J Viral Dis, 2022, 12(1):74-80.
[11]	Abaasa A, Hendrix C, Gandhi M, et al. Utility of different adherence measures for PrEP:patterns and incremental value[J]. AIDS Behav, 2018, 22(4):1165-1173. DOI URL
[12]	Dong MJ, Peng B, Liu ZF, et al. The prevalence of HIV among MSM in China:a large-scale systematic analysis[J]. BMC Infect Dis, 2019, 19(1):1000. DOI URL
[13]	国家卫生健康委员会. 遏制艾滋病传播实施方案(2019—2022年)[J]. 中国病毒病杂志, 2020, 10(1):47-50.
	National Health Commission of the People’s Republic of China. Implementation plan to curb the spread of AIDS(2019-2022)[J]. Chin J Viral Dis, 2020, 10(1):47-50.
[14]	Pečavar B, Kokošar Ulčar B, Kordiš M, et al. Pre-exposure prophylaxis for HIV with oral tenofovir disoproxil fumarate/emtricitabine in men who have sex with men:Slovenian national demonstration project[J]. Int J STD AIDS, 2021, 32(11):1060-1065. DOI URL
[15]	Jalil EM, Torres TS, Luz PM, et al. Low PrEP adherence despite high retention among transgender women in Brazil:the PrEParadas study[J]. J Int AIDS Soc, 2022, 25(3):e25896.
[16]	徐俊杰, 黄晓婕, 刘昕超, 等. 中国HIV暴露前预防用药专家共识[J]. 中国艾滋病性病, 2020, 26(11):1265-1271.
	Xu JJ, Huang XJ, Liu XC, et al. Expert consensus on HIV pre-exposure prophylaxis in China[J]. Chin J AIDS STD, 2020, 26(11):1265-1271.
[17]	Spinelli MA, Laborde N, Kinley P, et al. Missed opportunities to prevent HIV infections among pre-exposure prophylaxis users:a population-based mixed methods study,San Francisco,United States[J]. J Int AIDS Soc, 2020, 23(4):e25472.
[18]	Khalili P, Nadimi AE, Baradaran HR, et al. Validity of self-reported substance use:research setting versus primary health care setting[J]. Subst Abuse Treat Prev Policy, 2021, 16(1):66. DOI PMID
[19]	Yu XY, Xu C, Ni Y, et al. Pre-exposure prophylaxis(PrEP) adherence questionnaire:psychometric validation among sexually transmitted infection patients in China[J]. Int J Environ Res Public Health, 2021, 18(20):10980. DOI URL
[20]	Camp C, Saberi P. Facilitators and barriers of 2-1-1 HIV pre-exposure prophylaxis[J]. PLoS One, 2021, 16(5):e0251917.
[21]	Wilson IB, Fowler FJ Jr, Cosenza CA, et al. Cognitive and field testing of a new set of medication adherence self-report items for HIV care[J]. AIDS Behav, 2014, 18(12):2349-2358. PMID
[22]	Ojeda VD, Amico KR, Hughes JP, et al. Low disclosure of PrEP nonadherence and HIV-risk behaviors associated with poor HIV PrEP adherence in the HPTN 067/ADAPT study[J]. J Acquir Immune Defic Syndr, 2019, 82(1):34-40. DOI PMID
[23]	Knobel H, Alonso J, Casado JL, et al. Validation of a Simplified Medication Adherence Questionnaire in a large cohort of HIV-infected patients:the GEEMA Study[J]. AIDS Lond Engl, 2002, 16(4):605-613. DOI URL
[24]	Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence[J]. Med Care, 1986, 24(1):67-74. PMID
[25]	黄洁, 郝桂华, 陈章, 等. 维持性血液透析患者口服磷结合剂依从性问卷的汉化及信效度研究[J]. 中华现代护理杂志, 2017, 23(24):3098-3102.
	Huang J, Hao GH, Chen Z, et al. Reliability and validity research of Chinese Version of Simplified Medication Adherence Questionnaire in hemodialysis patients with oral phosphate binder[J]. Chin J Mod Nurs, 2017, 23(24):3098-3102.
[26]	Smith DK, Rawlings MK, Glick N, et al. Adherence to daily oral TDF/FTC for PrEP in community health center populations:the sustainable health center implementation PrEP pilot (SHIPP) study[J]. AIDS Behav, 2022, 26(2):350-360. DOI URL
[27]	Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials:the AACTG Adherence Instruments[J]. AIDS Care, 2000, 12(3):255-266. PMID
[28]	贾思艳, 黄玉玲, 杨淑娟. 污名化感知对50岁及以上HIV/AIDS患者抗病毒治疗服药依从性的影响[J]. 中国艾滋病性病, 2021, 27(12):1358-1362.
	Jia SY, Huang YL, Yang SJ. Impact of stigma on anti-retroviral therapy compliance of aged 50 and above HIV/AIDS patients[J]. Chin J AIDS & STD, 2021, 27(12):1358-1362.
[29]	Lu MY, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence[J]. AIDS Behav, 2008, 12(1):86-94. PMID
[30]	Egan JE, Ho K, Stall R, et al. Feasibility of short-term PrEP uptake for men who have sex with men with episodic periods of increased HIV risk[J]. J Acquir Immune Defic Syndr, 2020, 84(5):508-513. DOI PMID
[31]	Pasipanodya EC, Li MJ, Jain S, et al. Greater levels of self-reported adherence to pre-exposure prophylaxis(PrEP) are associated with increased condomless sex among men who have sex with men[J]. AIDS Behav, 2020, 24(11):3192-3204. DOI PMID
[32]	Hannaford A, Arens Y, Koenig H. Real-time monitoring and point-of-care testing:a review of the current landscape of PrEP adherence monitoring[J]. Patient Prefer Adherence, 2021, 15:259-269. DOI URL
[33]	Yager J, Castillo-Mancilla J, Ibrahim ME, et al. Intracellular te-nofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following tenofovir alafenamide:the TAF-DBS study[J]. J Acquir Immune Defic Syndr, 2020, 84(3):323-330. DOI URL
[34]	Koss CA, Hosek SG, Bacchetti P, et al. Comparison of measures of adherence to human immunodeficiency virus preexposure prophylaxis among adolescent and young men who have sex with men in the united states[J]. Clin Infect Dis, 2017, 66(2):213-219. DOI URL
[35]	Stalter RM, Baeten JM, Donnell D, et al. Urine tenofovir levels measured using a novel immunoassay predict human immunodeficiency virus protection[J]. Clin Infect Dis, 2020, 72(3):486-489. DOI URL
[36]	Jin X, Wang HY, Li H, et al. Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China:a multicentre RCT study protocol[J]. BMC Public Health, 2020, 20(1):1160. DOI URL
[37]	Chai PR, Vaz C, Goodman GR, et al. Ingestible electronic sensors to measure instantaneous medication adherence:a narrative review[J]. Digit Health, 2022, 8:20552076221083119.
[38]	Chai PR, Goodman GR, Bronzi O, et al. Real-world user experiences with a digital pill system to measure PrEP adhere-nce:perspectives from MSM with substance use[J]. AIDS Be-hav, 2022, 26(7):2459-2468.
[39]	Coy KC, Hazen RJ, Kirkham HS, et al. Persistence on HIV pre-exposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users,united states,2015 to 2017[J]. J Int AIDS Soc, 2019, 22(2):e25252. DOI URL
[40]	Marins LMS, Torres TS, Leite I, et al. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women:results from the PrEP brasil study[J]. PLoS One, 2019, 14(8):e0221281.
[41]	高岩, 章清, 孙美艳, 等. HIV感染者/AIDS患者服药依从性管理的系统评价再评价[J]. 中华护理杂志, 2021, 56(4):604-610. DOI URL
	Gao Y, Zhang Q, Sun MY, et al. Effectiveness of management of medication compliance to antiretroviral therapy in HIV/AIDS patients:an overview of reviews[J]. Chin J Nurs, 2021, 56(4):604-610.